CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

NCT02580448 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer of the Breast
Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer
Male Breast Cancer
Triple Negative Breast Cancer
ER+ Breast Cancer

Interventions

DRUG: Seviteronel

Sponsor

Innocrin Pharmaceutical